Lexeo Therapeutics Inc
LXEO8.190USD
-0.230-2.73%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
449.89MMarket Cap
LossP/E TTM
More Details of Lexeo Therapeutics Inc Company
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Lexeo Therapeutics Inc Info
Ticker SymbolLXEO
Company nameLexeo Therapeutics Inc
IPO dateNov 03, 2023
CEOMr. R. Nolan Townsend
Number of employees72
Security typeOrdinary Share
Fiscal year-endNov 03
Address345 Park Avenue South
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10010
Phone12125479879
Websitehttps://www.lexeotx.com/
Ticker SymbolLXEO
IPO dateNov 03, 2023
CEOMr. R. Nolan Townsend
Company Executives of Lexeo Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
45.00K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
11.04K
+127.67%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
6.70K
+133.18%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Paula H. J. Cholmondeley
Ms. Paula H. J. Cholmondeley
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
45.00K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
11.04K
+127.67%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
6.70K
+133.18%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Oct 29
Updated: Wed, Oct 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Balyasny Asset Management LP
5.49%
Janus Henderson Investors
5.05%
Citadel Advisors LLC
4.94%
Other
71.60%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Balyasny Asset Management LP
5.49%
Janus Henderson Investors
5.05%
Citadel Advisors LLC
4.94%
Other
71.60%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.93%
Investment Advisor/Hedge Fund
14.45%
Venture Capital
14.21%
Investment Advisor
8.03%
Private Equity
6.60%
Research Firm
3.41%
Individual Investor
0.51%
Bank and Trust
0.04%
Family Office
0.02%
Other
22.80%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
189
48.60M
66.59%
+5.10M
2025Q2
181
40.60M
122.31%
+231.62K
2025Q1
174
34.46M
103.80%
-3.48M
2024Q4
155
35.40M
107.08%
+416.99K
2024Q3
127
33.64M
101.76%
+2.87M
2024Q2
112
31.41M
96.45%
+1.88M
2024Q1
92
30.30M
97.67%
+5.87M
2023Q4
45
23.22M
87.68%
+3.57M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
4.42M
8.19%
--
--
Jun 30, 2025
Balyasny Asset Management LP
4.01M
7.42%
+4.01M
--
Jun 30, 2025
Janus Henderson Investors
3.68M
6.82%
-873.54K
-19.17%
Jun 30, 2025
Citadel Advisors LLC
3.61M
6.68%
+884.60K
+32.48%
Jun 30, 2025
Affinity Asset Advisors LLC
3.59M
6.65%
+2.11M
+142.38%
Jun 30, 2025
Vestal Point Capital, LP
3.23M
5.98%
+2.09M
+184.11%
Jun 30, 2025
Millennium Management LLC
2.84M
5.25%
+902.91K
+46.70%
Jun 30, 2025
Longitude Capital Management Co., LLC
2.77M
5.12%
--
--
Sep 30, 2024
Woodline Partners LP
2.57M
4.76%
+1.74M
+207.30%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
iShares Micro-Cap ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
